Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
November 22 2022 - 6:30AM
Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the
“Company”), a biotechnology company developing novel therapeutic
candidates targeting ferroptosis, an emerging new anti-cancer
mechanism resulting in iron mediated cell death for drug resistant
and devastating cancers, will present at the 2022 RHK Capital
Disruptive Growth Conference hosted at Reed Smith in New York City
on December 5-6, 2022.
Mr. Randy Milby, Founder and Chief Executive Officer of
Hillstream BioPharma will present on Tuesday December 6th at 11:40
am ET. Mr. Milby will be available for one-on-one meetings and also
for additional appointments with members of the investment
community. The presentation will be webcast. To access the live
webcast and subsequent archived recordings for the presentation,
please visit the Hillstream BioPharma website at:
www.hillstreambio.com. To register for the conference and
participate in 1-on-1 meetings please click this link,
www.DisruptNYC.com
“We look forward to the opportunity to participate in this
conference to discuss our game changing cancer fighting treatment
methodology with a broad scope of individuals,” said Mr. Milby.
“Additionally, this event will allow us to network with other key
players in the drug development industry.”
About the RHK Capital Disruptive Growth
Conference The RHK Capital Disruptive Growth
Conference is a two-day conference offering the exclusive
opportunity to discover growth companies with disruptive
technologies and business models focusing on solutions to unmet
medical needs.
About RHK Capital
RHK Capital is a pioneer in the revival and re-purpose of the
rights offering structure, with additional experience in warrant
offerings, IPOs, primary offerings, follow-on offerings, registered
directs, confidentially marketed public offerings, private
placements, secondaries, exchange offers, mergers and acquisitions,
stock and asset sales, restructurings, recapitalization and other
related investment banking activities. Richard H. Kreger and Bruce
Ryan co-founded RHK Capital.
About Hillstream BioPharma Inc.Hillstream
BioPharma, Inc. is a biotechnology company developing novel
therapeutic candidates targeting ferroptosis, an emerging new
anti-cancer mechanism resulting in iron mediated cell death for
drug resistant and devastating cancers. Hillstream’s most advanced
candidate is HSB-1216, an IMCD modulator, targeting a variety of
solid tumors. The active drug in HSB-1216 was found to be
efficacious in a clinical pilot study in Germany in devastating
cancers, including triple negative breast cancer and epithelial
carcinomas. Hillstream intends to initiate IND discussions with the
FDA in first half of 2023. Hillstream uses Quatramer™, our
proprietary tumor targeting platform, to enhance the uptake of
HSB-1216 in the tumor microenvironment with an extended duration of
action and minimal off-target toxicity. For more information,
please visit: www.hillstreambio.com.
Investor Relations
Contact:Email: investorrelations@hillstreambio.com
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hillstream BioPharma (NASDAQ:HILS)
Historical Stock Chart
From Sep 2023 to Sep 2024